Drug profile

The FDA adverse-event record for Ibr, Bvd Cp Type1, Ncp Type 1 And 2, Pi3, Brsv, Killed Virus

12 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Ibr, Bvd Cp Type1, Ncp Type 1 And 2, Pi3, Brsv, Killed Virus. See the species affected, top reactions, and outcomes below.

12
adverse-event reports
66.7%
death-coded share
Cattle
most-reported species
8
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
8
Deaths Reported
66.7%
Death Rate

Active Ingredients

Ibr, Bvd Cp Type1, Ncp Type 1 And 2, Pi3, Brsv, Killed Virus

Administration Routes

ParenteralUnknownSubcutaneous

Species Affected

Cattle 12

Most Affected Breeds

Aberdeen Angus 4
Cattle (unknown) 2
Crossbred Bovine/Cattle 2
Holstein-Friesian also known as Holstein 1
Mixed (Cattle) 1
Beefmaster 1
Red Angus 1

Most Reported Reactions

Death 8
Necropsy performed 3
Respiratory tract infection NOS 2
Respiratory signs 2
Lack of awareness 1
Injection site pain 1
Downer animal 1
Pneumonia 1
Lack of efficacy (bacteria NOS) 1
Lack of efficacy (endoparasite) - Trichostrongylus 1
Lack of efficacy - NOS 1
Foam in the mouth 1

Outcome Breakdown

Died
8 (57.1%)
Outcome Unknown
4 (28.6%)
Recovered/Normal
2 (14.3%)

Ibr, Bvd Cp Type1, Ncp Type 1 And 2, Pi3, Brsv, Killed Virus Adverse Event Insights

12 reports name Ibr, Bvd Cp Type1, Ncp Type 1 And 2, Pi3, Brsv, Killed Virus; 8 recorded a death outcome (66.7% of reported events, not a population-level mortality rate). Active ingredient: Ibr, Bvd Cp Type1, Ncp Type 1 And 2, Pi3, Brsv, Killed Virus. Administration routes: Parenteral, Unknown, Subcutaneous.

By species: Cattle (12 reports). By breed: Aberdeen Angus (4), Cattle (unknown) (2), Crossbred Bovine/Cattle (2).

Leading clinical signs: Death (8), Necropsy performed (3), Respiratory tract infection NOS (2), Respiratory signs (2). Outcome, 14 coded reports: Died leads at 57.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.